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shown, however, that the death rate from lung cancer
was not significantly different in patients who were
actively screened than in patients who were not
(3.2/1000 patients vs 3.0/1000 patients in the Mayo
lung project3). Even if some of the methods used in
those trials were criticized, their failure to show a sig-
nificant reduction in cancer death rates was and still is
considered strong evidence against screening. These
techniques may also have some potential to be harmful
through false positive radiographs (0%-10%/year), false
positive cytologic reports (0%-1%/year), and chances
of incorrect cancer diagnosis (0%-1%/year).4
More recently, these techniques have evolved to those
of screening by low-dose helical computed tomography
(CT) and use of specific biomarkers for lung cancer.
The Early Lung Cancer Action Project (ELCAP)5
notably looked at the usefulness of annual helical low-
dose CT scanning in 1000 heavy smokers over the age
of 60 years. Helical CT detected 233 individuals (23%)
with noncalcified nodules, but in only 27 (12%) were
the nodules malignant. Of these 27 patients, 16 are
included in the current report by Altorki and associ-
ates,6 which suggests that CT scan can detect lung can-
cer at an earlier stage than chest radiographs. This
would appear obvious since CT scanning is much more
sensitive to detect small nodules than standard radio-
graphs. Whether these findings translate into actual
improvements in lung cancer death rates (the most
important end point in cancer screening) is unknown,
not only because the number of patients in the CT group
is small, but also because no long-term follow-up is
given for this cohort. One should also note that 91% of
patients in the CT group had adenocarcinoma, a ratio
that does not reflect the true proportions of this tumor
among all histologic types of lung cancer.
As shown by the original data from ELCAP,5 one of
the drawbacks of screening with low-dose helical CT is
the number of detected nodules that are initially inter-
preted as being nonmalignant. If one was to keep the
same ratio as reported by ELCAP, screening by CT
would translate into finding approximately 220,000
presumably nonmalignant nodules in a screened popu-
lation of 1,000,000. What will be done with these
patients will largely be left to the judgment of individ-
ual physicians, although this judgment is likely to be
influenced by the patient’s anxiety or the physician’s
O ver the past 15 to 20 years, lung cancer has becomethe most prevalent form of malignancy in men and
the second most common in women. In addition, it has
also become the leading cause of cancer death in both
men and women. Unfortunately, these statistics are
unlikely to change in the near future even though the
number of smokers in the United States has significant-
ly decreased to 20% to 25% of the population.
In the management of lung cancer, surgical resection
offers some possibility for cure, although most new
patients are first seen when it is already too late to oper-
ate. Indeed, 5-year survival figures are consistently in
the range of 10% to 12% even if they rise to 25% to
30% in those few individuals who can have complete
resection of their tumors. The disease can, however, be
cured in up to 70% of cases if surgically managed while
still in its earliest stages (clinical stages Ia and Ib).
Because of these better survival figures, it is tempting to
assume that with lung cancer screening, tumors will be
diagnosed at an earlier stage and cure rates will be high-
er. This seems even more likely if one considers that
lung cancer should easily be identifiable on chest radio-
graphs or by sputum cytology. In this context, it may be
worth noting that tumors smaller than 2 cm are not nec-
essarily early-stage neoplasms (up to 20% already have
N2 status); on the other hand, some of these tumors can
be slow growing so that 5-year survivals may not be an
accurate way of reporting results.
The two methods traditionally used for early detec-
tion of lung cancer are standard chest radiographs and
sputum cytologic examination. Chest radiographs can
detect lung nodules of 0.8 to 1 cm in diameter, whereas
sputum cytology will be “positive” in 30% to 40% of
endobronchial lesions. Both techniques are inexpensive
and excellent for individual cases. Three randomized
studies1-3 done in the 1970s and supported by research
contracts from the National Institutes of Health have
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fear of being involved in legal actions if a malignant
nodule is diagnosed too late. These are some of the rea-
sons why I think that screening by CT should be
reserved for very high-risk patients such as those heavy
smokers (or former heavy smokers) with a personal or
family history of any type of malignancy or with occu-
pational exposure to known carcinogens. Indeed, the
highest risk group for lung cancer is the group of
patients with prior lung cancer (2%-5%/year). The
problem of over diagnosis, that is, diagnosing a lung
cancer that is unlikely to become life-threatening, is a
nonissue because it has been repeatedly shown that
most untreated lung cancers are likely to progress and
cause death within 5 years of their diagnosis. In the
three screening programs previously mentioned,1-3 the
5-year survival of patients with screen-detected lung
cancer who did not undergo surgery was below 10%.
Perhaps a more specific method of screening patients
at risk for lung cancer is through the use of biomarkers
applied to sputum specimens. In 1988, Tockman and
associates7 reported on two monoclonal antibodies
(703D4 and 624H12) that were identified as biomark-
ers of lung cancer. When applied to the Johns Hopkins
early lung cancer specimens, these antibodies together
showed a sensitivity of 91% and a specificity of 88%
for the diagnosis of lung cancer within 2 years. Since
then, clinical trials to evaluate these biomarkers have
been designed with the hypothesis that screening with
immunostaining techniques will increase the percent-
age of detected stage I lung cancers at least 3-fold.8 It
is of interest to note that sputum for cytologic analysis
is best obtained after saline aerosol induction and that
microscopic workstations have already been developed
to extract positive immunostained cells. It may soon be
possible that chemo-preventive agents delivered by
inhalation will be given to destroy such early tumors
before they become invasive.
Because of major advances in these new technolo-
gies, lung cancer screening programs should be
reopened, perhaps by combining the use of low-dose
helical CT and immunostaining techniques. Initially, at
least, eligibility for those programs should be restricted
to very high-risk patients.
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